China Pharma Hlgs (CPHI) Stock
Very small pharmaceutical company with limited public information. Here's the price, business snapshot, and what's worth knowing about China Pharma Hlgs in September 2026.
China Pharma Holdings Inc (ticker: CPHI) is a very small-capitalisation pharmaceutical company with a market value of about $5.84 million. Publicly available information on its operations, product pipeline and revenue is limited, which is common among micro-cap firms. Such companies may be involved in manufacturing, generics or early-stage research, but specifics can vary and should be confirmed from primary filings. Micro-cap status typically means low trading volumes, greater price volatility and heightened sensitivity to operational, regulatory and currency risks. Corporate governance and transparency may also differ from larger peers. Investors interested in CPHI should review regulatory filings, audited accounts and company announcements and consider liquidity constraints. For most portfolios, exposure to a micro-cap pharmaceutical is speculative and should be small relative to overall holdings. This summary is educational only and not personalised advice; values can fall as well as rise and returns are not guaranteed.
About This Stock
CHINA PHARMA HLGS INC
CPHI
Current Price
$0.76
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Ticker
CPHI
Market Cap
$32.71M
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Financial Health
China Pharma is generating low revenue and profit margins, indicating potential financial challenges ahead.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Micro-cap market dynamics
Low market capitalisation often leads to pronounced price swings and limited liquidity; investors should be prepared for higher volatility.
China exposure factors
Regulatory, currency and reporting environments in China can materially affect performance, so review cross-border risks and disclosures carefully.
Sector specifics to watch
Pipeline updates, approvals or partnerships can move the share price significantly, though outcomes are uncertain and subject to regulatory review.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.